Identification of a Soluble Form of B7-H1 That Retains Immunosuppressive Activity and Is Associated with Aggressive Renal Cell Carcinoma

Xavier Frigola¹,4, Brant A. Inman⁵, Christine M. Lohse², Christopher J. Krco¹,4, John C. Cheville³, R. Houston Thompson⁴, Bradley Leibovich⁴, Michael L. Blute⁴, Haidong Dong¹,4, and Eugene D. Kwon¹,4

Abstract

Purpose: Release of inhibitory coregulatory proteins into the circulation may represent one mechanism by which tumors thwart immune responses. Our objective was to determine whether soluble B7-H1 (sB7-H1) levels in patients with clear cell renal cell carcinoma (ccRCC) are associated with pathologic features and patient outcome.

Experimental Design: We developed an ELISA for quantification of sB7-H1 in biological fluids. Biochemical confirmation of the measured analyte as sB7-H1 was done by protein microsequencing using supernates from tumor cell lines. Biological activity of sB7-H1 was assessed in vitro utilizing T-cell apoptosis assays. We tested sB7-H1 levels in the sera from 172 ccRCC patients and correlated sB7-H1 levels with pathologic features and patient outcome.

Results: sB7-H1 was detected in the cell supernatants of some B7-H1–positive tumor cell lines. Protein sequencing established that the measured sB7-H1 retained its receptor-binding domain and could deliver proapoptotic signals to T cells. Higher preoperative sB7-H1 levels were associated with larger tumors (P < 0.001), tumors of advanced stage (P = 0.017) and grade (P = 0.044), and tumors with necrosis (P = 0.003). A doubling of sB7-H1 levels was associated with a 41% increased risk of death (P = 0.010).

Conclusion: Our observations suggest that sB7-H1 may be detected in the sera of ccRCC patients and that sB7-H1 may systemically impair host immunity, thereby fostering cancer progression and subsequent poor clinical outcome.

Clin Cancer Res; 17(7); 1915–23. ©2011 AACR.

Introduction

Considerable uncertainty exists about the existence and molecular forms of circulating coregulatory molecules. Soluble forms of B7 family coregulatory proteins (including B7.1, B7.2, CD28, CTLA-4, and B7-H4) in sera of patients with malignancy, infection, and autoimmune disorders have been claimed to be detected (1–5), invariably without accompanying biochemical proof. Whether soluble B7-H1 (sB7-H1) exists, too, remains an unresolved issue. Conflicting B7-H1 serologic studies have led to a misperception that the existence of sB7-H1 is firmly established (6–8). Wan and colleagues suggested that sB7-H1 is present and elevated among rheumatoid arthritis patients. However, these results, largely obtained with potentially cross-reacting polyclonal antibodies, were questioned (7) and not confirmed (8).

Prompted by these contradictory reports, and because membrane expression of B7-H1 among a small percentage of tumor cells in patients with clear cell renal cell carcinoma (ccRCC) affords a dismal prognosis (9, 10), we developed a sB7-H1 ELISA and biochemically confirmed the identity of the detected protein. We then measured levels of sB7-H1 in ccRCC patient and normal control sera and correlated sB7-H1 levels with pathologic features of ccRCCs and patient outcome.

Materials and Methods

Development of antibodies against B7-H1

The detection antibody, 5H1-A3, was subcloned from the anti-B7-H1 producing 5H1 hybridoma (11). To generate the capture antibody, 2.2B, 624MEL cells were transfected with full-length human B7-H1 (11) and injected (5 × 10⁶ cells per injection) intraperitoneally into Balb/c mice weekly for 6 weeks. Immune splenocytes were isolated and fused with A38 cells to form a hybridoma by standard techniques (12). 5H1-A3 and 2.2B...
hybridoma supernatants were screened by ELISA for reactivity against a recombinant human protein B7-H1 human immunoglobulin (Ig) G (IgG; R&D Systems) which contains only the extracellular domain of B7-H1 (amino acids 19–239) and for the absence of cross-reactivity to an irrelevant recombinant protein P-selectin-human IgG (BD Biosciences) or mouse Igs (Sigma).

**Development of sandwich ELISA for sB7-H1**

We developed a sandwich ELISA by using paired mouse IgG1 monoclonal antibodies (2.2B and 5H1-A3) raised against the extracellular domain of human B7-H1. We validated the specificity of each individual antibody by immunohistochemistry, indirect ELISA (data not shown), and flow cytometry (Supplementary Fig. S1A). Both antibodies bind to the extracellular domain of B7-H1 and to different sites on the B7-H1 molecule (Supplementary Fig. S1B and C). The configuration of 2.2B (capture) and 5H1-A3 (detection) exhibits an optimal detection range (C2.5–C97.5) between 0.086 and 3.67 ng/mL, with a coefficient of variation of 10% (Supplementary Fig. S2). The assay is specific for B7-H1 and does not exhibit cross-reactivity to other B7-H homologues (B7-H2, B7-H3, B7-H4, B7.1, or PD-1; all from R&D Systems), Ig, or third-party recombinant protein P-selectin (BD Biosciences) expressing a shared Fc carrier element (Fig. 1A). Binding of 2.2.B or 5H1-A3 to B7-H1 in the ELISA can be blocked by preincubating appropriate standards with antibody (data not shown).

2.2B was used as the plate-fixed capture antibody and biotinylated 5H1-A3 was used as the detection antibody. Biotinylation was done using a solid-phase kit (Pierce). Individual ELISA steps involved 3 washes, using a PBS + 0.05% Tween-20 buffer. High-binding polystyrene plates (Corning Life Sciences) were coated for 2 hours at 21°C with 0.2 μg per well of 2.2B. Free binding sites were blocked with 200 μL per well of Superblock (Pierce) for 1 hour at 21°C. After washing, 50 μL of sample was added to 50 μL of assay buffer [PBS + 1% bovine serum albumin (BSA)] and incubated overnight at 4°C. Biotinylated 5H1-A3 (100 μL per well at 1 μg/mL diluted in PBS + 0.1% BSA) was added and incubated for 1 hour at 21°C. A total of 100 μL per well of horseradish peroxidase–conjugated streptavidin (BD Biosciences) diluted in PBS + 0.1% BSA was added and incubated for 1 hour at 21°C. Plates were developed with tetramethylbenzidine (Pierce), stopped using 0.5N H2SO4, and read at 450 nm with a Benchmark Plus plate reader and associated software (Bio-Rad). For calibration, each plate was loaded with parallel dilutions of recombinant B7-H1 protein.

**Translational Relevance**

Expression of membrane B7-H1 immunoinhibitory molecules by clear cell renal cell carcinomas (ccRCC) is associated with poor patient outcome. Mechanisms by which membrane B7-H1–positive tumors cells, detected immunohistochemically, thwart antitumoral responses are largely conjectural. Using a B7-H1–specific ELISA, we determined that higher preoperative levels of circulating soluble B7-H1 (sB7-H1) molecules in ccRCC patients were associated with aggressive pathologic features and an increased risk of death. Release of sB7-H1 molecules may be a tumor mechanism for impairing antitumoral responses systemically. Treatments to inactivate or remove serum sB7-H1 molecules may be clinically beneficial.
fusion protein (R&D Systems), ranging in concentration from 0.07 to 10 ng/mL.

Calibration of the B7-H1 ELISA against standard B7-H1 dilution curves was done by fitting a 4-parameter logistic regression model, using the drc package for R (13, 14). A calibration plot with 95% confidence and prediction intervals was generated by 16 consecutive and independent assays using concentrations of B7-H1 fusion protein ranging from 10 μg/mL to 1.2 pg/mL. The calibration model revealed a coefficient of determination (R²) of 0.959, representing an excellent model fit and minimal interassay variability. For the specificity determinations, generalized additive regression models were constructed with the mgcv package for R (15), and smooth fits of the results for the nonspecific proteins were plotted and overlaid.

Cancer cell lines

Human cancer cell lines 624MEL, 293T, Jurkat, 22RV1, DU145, PC3, Caki-2, J82, Karps-299, and SUDHL-1 were purchased from American Type Culture Collection and propagated in complete media (RPMI + 10% FBS, 20 mmol/L HEPES, and penicillin/streptomycin). The 624MEL/B7-H1 cell line containing the human full-length B7-H1 sequence was generated as previously described (11). BT10B is a spontaneously immortalized bladder cancer cell line established in our laboratory from a cystectomy specimen classified as a high-grade urothelial carcinoma. BT10B expresses uroplakin III and cytokeratin-20, indicative of urothelial origin (16). To test for the presence of tumor-derived sB7-H1, cells were cultured for 3 to 5 days. Supernatants were collected, centrifuged at 2,000 × g for 10 minutes to remove cellular debris, and tested using the ELISA described earlier.

Protein purification and sequence identification by tandem mass spectrometry

Nonadherent sB7-H1–positive cell lines Karps-299 and SUDHL-1 were grown in roller bottles for 7 to 10 days in complete media. Supernatants were harvested before becoming acidic and while cell viability remained greater than 98%. To eliminate cell debris, enriched media were centrifuged at 2,000 × g for 20 minutes, followed by clarification through 0.45-μm filters. Processed supernates were passed through a 2.2B affinity column coupled to a BioLogic LP monitor (Bio-Rad). Following sB7-H1 capture, the column was thoroughly washed and 1-mL fractions was generated by 16 consecutive and independent calibration plot with 95% confidence and prediction intervals was generated by 16 consecutive and independent assays using concentrations of B7-H1 fusion protein ranging from 10 μg/mL to 1.2 pg/mL. The calibration model revealed a coefficient of determination (R²) of 0.959, representing an excellent model fit and minimal interassay variability. For the specificity determinations, generalized additive regression models were constructed with the mgcv package for R (15), and smooth fits of the results for the nonspecific proteins were plotted and overlaid.

Apoptosis assay for activated human T cells

Normal human peripheral blood mononuclear cells were isolated from leukoreduction filters (Pall) as previously described (19, 20). CD4 and CD8 T cells were obtained by negative magnetic isolation (Miltenyi Biotech). Cells were placed in 96-well plates precoated with 2 μg/mL of anti-human CD3 (clone UCHT1; BD Biosciences) and cultured 3 days in complete media. A total of 10 μg/mL recombinant human B7-H1/Fc or P-selectin/Fc fusion protein (R&D Systems) was preincubated with 30 μg/mL of functional grade B7-H1 blocking antibody (clone MIH1) or an isotype control antibody (both from eBioscience) for 30 minutes at 4°C. The mixture was then added to cultures of activated T cells. Following an overnight incubation, T cells were harvested and stained for Annexin V (BD Biosciences) and propidium iodide (PI; Sigma). Relative percentages of apoptotic (Annexin-V”PI-”) CD4 and CD8 T cells were quantified by flow cytometry (FACSCalibur; BD Biosciences) in combination with FlowJo analysis software (Tree Star). Paired t tests were used to compare apoptosis among activated T cells.

cCRCC patient selection

We designed a pilot study to test whether sB7-H1 was present and detectable in the sera of cCRCC patients. On approval from the Institutional Review Board, we reviewed the Mayo Clinic Nephrectomy Registry, which contains more than 5,000 patients treated surgically for a solid renal mass since 1970. From this registry, we identified a consecutive series of 650 patients treated surgically for unilateral, sporadic cCRCC between May 2003 and December 2007. Histologic subtype and pathologic features were obtained by a review of all microscopic slides from the nephrectomy specimens by a urologic pathologist (J.C.C.) according to the Union Internationale Contre le Cancer, American Joint Committee on Cancer, and Heidelberg guidelines (21, 22) without knowledge of patient outcome.

To ensure complete patient follow-up, a registered nurse abstractor assigned to the registry reviews the medical records of all patients who are still alive annually. For patients who have died, the nurse abstractor reviews a number of sources to determine cause of death including death certificates, medical records, and correspondence with the patients’ families and local physicians. To date,
less than 3% of patients in the registry have been lost to follow up.

**Serum collection and sB7-H1 analyses**

 Biospecimen collection for patients in the registry began in May 2003. Of the 650 ccRCC patients identified earlier, 172 consented to provide preoperative blood samples for our biospecimen repository and had archived sera available for study. There was not a statistically significant difference in overall survival between patients who did and did not consent to provide blood samples ($P = 0.38$; log-rank test). Serum samples were stored at $-80^\circ$C until used.

To perform the B7-H1 ELISA, serum samples were thawed at $4^\circ$C and tested in duplicate along with protein standards and controls. The technician performing the B7-H1 ELISA was blinded to the pathologic features and outcome of the ccRCC patients analyzed. Associations of the average of the duplicate sB7-H1 levels with clinical and pathologic features of the ccRCC patients were evaluated using Spearman rank correlation coefficients and the Kruskal–Wallis and Wilcoxon rank-sum tests. Associations of sB7-H1 levels with patient outcome following surgery were evaluated using Cox proportional hazards regression models, both univariately and after adjusting for the stage, size, grade, and necrosis (SSIGN) score (23) developed specifically for patients with ccRCC. For these analyses, sB7-H1 levels were transformed to the log(2) scale so that they were approximately normally distributed.

**sB7-H1 in normal controls and ELISA reproducibility**

To compare sB7-H1 levels between ccRCC patients and normal controls and to evaluate intra- and interassay reproducibility, we randomly selected 50 of the 172 ccRCC patients and identified 50 normal controls (mean age 52 years; 30 men and 20 women). Sera from the normal controls were obtained from healthy volunteers undergoing blood donation at the Mayo Clinic Department of Transfusion Medicine. sB7-H1 levels in these 100 specimens (50 ccRCC patients and 50 normal controls) were again tested in duplicate in 2 consecutive experiments. sB7-H1 levels were compared between ccRCC patients and normal controls univariately and after adjusting for age and gender with a Wilcoxon rank-sum test and a linear model of the log(2)-transformed sB7-H1. The intra- and interassay reproducibility of the B7-H1 ELISA was assessed using Lin’s concordance correlation coefficient (24). This measure ranges from 0.0 to 1.0, with higher values indicating a greater level of agreement or reproducibility.

**Results**

**ELISA measurement of sB7-H1 in the culture supernatants of human cancer cell lines**

To determine whether tumor cell lines release sB7-H1 in vitro, the culture supernatants from membrane B7-H1–positive and B7-H1–negative (Supplementary Fig. 3) cancer cell lines were tested using the B7-H1 ELISA (Fig. 1B). sB7-H1 was detected in the supernates of membrane B7-H1–positive cell lines BT10B (bladder cancer), DU145 (prostate cancer), 624ME/L/B7-H1 (B7-H1–transfected), and Karpas-299 and SU-DHL-1 (both lymphomas). In contrast, sB7-H1 was not detected among supernates from membrane B7-H1–negative cell lines (Jurkat, 293T, 624ME/L, and 22Rv1). Cell lines expressing reverse transcriptase PCR B7-H1 mRNA (Supplementary Fig. 4) were positive for membrane B7-H1.

**Purification of sB7-H1 from tumor cell supernatants and sB7-H1 protein sequencing**

To study the putative protein sequence of sB7-H1, we carried out affinity chromatography with a 2.2B [capture monoclonal antibody (mAb)]–coupled column, using cell culture supernatant from sB7-H1–positive SU-DHL-1 cells (Fig. 2A). sB7-H1 ELISA–positive soluble protein fractions were pooled, subjected to protein electrophoresis, and immunoblotted with 5H1-A3 (detection) biotin-labeled mAb. A band (Fig. 2B) was detected corresponding to a molecular weight of approximately 45 kDa, consistent with reported molecular weight of B7-H1 (25–27). Protein sequencing of the 45-kDa band determined that it corresponded to the N-terminus of B7-H1 and contained the Ig-V ligand–binding domain required for interaction with PD-1, the cognate receptor for B7-H1 (Fig. 2C). Similar results were obtained with supernates from other sB7-H1–positive cells including Karpas-299 and BT10B (data not shown). No detectable sB7-H1 material was collected from 2.2B affinity columns, using supernates from membrane B7-H1–negative tumor cell lines (data not shown).

**Effect of sB7-H1 on activated CD4 and CD8 T-cell apoptosis**

Protein sequencing of the 45-kDa bands indicated retention of PD-1–binding domain by sB7-H1 molecules, suggesting that sB7-H1 protein may be biologically active and capable of triggering apoptotic signals in target T cells. Bead-purified human CD4 or CD8 T cells were activated with anti-CD3 for 3 days. Activation was confirmed by increased expression of PD-1 (Fig. 3A). Activated CD4 or CD8 T cells were cocultured with soluble recombinant B7-H1/Fc (or control fusion protein), preadsorbed with either B7-H1 blocking (MIH1) or isotype control antibody. After 16 hours, cells were harvested and analyzed for apoptotic activity. Exposure to sB7-H1/Fc increased apoptosis of activated CD4 T cells ($P = 0.031$; Fig. 3B, left) to a greater extent than CD8 T cells ($P = 0.276$; Fig. 3B, right). Apoptosis of CD4 T cells was mitigated by preincubation with specific blocking antibody ($P = 0.037$). Control soluble P-selectin/Fc failed to alter frequencies of apoptotic CD4 or CD8 T cells (Fig. 3B). Therefore, sB7-H1, which retains the PD-1–binding domain, can deliver immunosuppressive signals to T cells.
ELISA measurement of sB7-H1 in the sera of ccRCC patients

Clinical and pathologic features for the 172 ccRCC patients studied are summarized in Table 1. Mean age was 62 years (median: 62; range: 27–90), and mean SSIGN score was 3.8 (median: 2; range: 0–15). Among the 24 patients classified as M1 at nephrectomy, 5 were treated preoperatively with sunitinib, 1 with sorafenib, 1 with interferon a, and 1 with low-dose interleukin-2. Mean sB7-H1 level in the 172 ccRCC patient sera studied was 0.34 ng/mL (median: 0.23; range: 0–4.40); 7 patients (4%) had undetectable sB7-H1 levels. Associations of preoperative sB7-H1 levels with clinical and pathologic features are summarized in Table 1 and some selected associations are depicted in Figure 4. Preoperative sB7-H1 levels tended to increase as tumor extent and aggressiveness increased. There were statistically significant positive correlations between sB7-H1 levels and tumor size (correlation coefficient: 0.26; P < 0.001) and SSIGN score (correlation coefficient: 0.24; P = 0.001). Patients having tumors extending beyond the confines of the kidney (i.e., pT3a, pT3b, pT3c, or pT4) had significantly higher sB7-H1 levels than patients with localized tumors (P = 0.017). There was also a trend for higher sB7-H1 levels among patients with distant metastases at surgery (P = 0.076). Patients with high-grade or necrotic tumors had significantly higher levels of sB7-H1 than patients with low-grade (P = 0.044) or non-necrotic tumors (P = 0.003).

At last follow-up, 39 of the 172 patients under study had died at a mean of 2.3 years following surgery (median: 2.0; range: 0.1–6.2), including 23 who died from RCC. Among the 133 patients still alive at last follow-up, the mean time from surgery to last follow-up was 3.8 years (median: 3.6; range: 0.1–7.3); only 4 (3%) of these patients had fewer than 2 years of follow-up. The HR for the univariate association of the log(2)-transformed sB7-H1 with death from any cause was 1.41 (95% CI: 1.08–1.83; P = 0.010), indicating that a doubling of sB7-H1 was associated with a 41% increase in the risk of death. The HR for the association of log(2) sB7-H1 with death after adjusting for the SSIGN score was 1.29 (95% CI: 0.95–1.76; P = 0.11).

sB7-H1 in normal controls and ELISA reproducibility

sB7-H1 levels were significantly elevated for the 50 randomly selected ccRCC cases compared with normal controls (P < 0.001), even after adjusting for age and
gender ($P = 0.016$). Mean sB7-H1 level for the 50 ccRCC patients was 0.42 ng/mL (median: 0.25; range: 0–6.21) compared with 0.20 ng/mL (median: 0.21; range: 0.13–0.57) for the 50 normal controls. Lin’s concordance correlation coefficient for the duplicate sB7-H1 levels measured during the first experiment was 0.99 ($P < 0.001$), indicating nearly perfect intra-assay reproducibility. Lin’s concordance correlation coefficient for the average of the duplicate sB7-H1 levels evaluated in 2 consecutive experiments was 0.74 ($P < 0.001$), indicating substantial interassay reproducibility.

### Discussion

B7-H1, an immunoinhibitory molecule expressed on the surface of activated T cells and macrophage-lineage cells (28), is aberrantly expressed on the membrane of many human tumors including kidney (9), bladder (29), ovary (30), breast (31), and stomach cancers (32) and lymphoma (33). We have reported that patients with ccRCC expressing even low amounts of membrane B7-H1–positive cells in their primary tumors or their metastases exhibit an increased risk of progression and cancer-specific death.

### Table 1. Associations of preoperative sB7-H1 levels (ng/mL) with clinical and pathologic features for 172 ccRCC patients

<table>
<thead>
<tr>
<th>Feature</th>
<th>n (%)</th>
<th>Mean sB7-H1 (median; range)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at surgery, y</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;65</td>
<td>96 (56)</td>
<td>0.32 (0.22; 0–3.00)</td>
<td>0.308</td>
</tr>
<tr>
<td>≥65</td>
<td>76 (44)</td>
<td>0.36 (0.26; 0–4.40)</td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td>45 (26)</td>
<td>0.40 (0.24; 0–4.40)</td>
<td>0.438</td>
</tr>
<tr>
<td>Men</td>
<td>127 (74)</td>
<td>0.32 (0.22; 0–3.00)</td>
<td></td>
</tr>
<tr>
<td>Tumor size, cm</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;5</td>
<td>75 (44)</td>
<td>0.28 (0.21; 0–2.25)</td>
<td>0.063</td>
</tr>
<tr>
<td>5 to &lt;7</td>
<td>37 (22)</td>
<td>0.32 (0.24; 0.02–3.00)</td>
<td></td>
</tr>
<tr>
<td>7 to &lt;10</td>
<td>32 (19)</td>
<td>0.49 (0.26; 0–4.40)</td>
<td></td>
</tr>
<tr>
<td>&gt;10</td>
<td>28 (16)</td>
<td>0.37 (0.29; 0–1.25)</td>
<td></td>
</tr>
<tr>
<td>2002 Primary Tumor Classification</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pT1a, pT1b</td>
<td>102 (59)</td>
<td>0.29 (0.22; 0–3.00)</td>
<td>0.017</td>
</tr>
<tr>
<td>pT2</td>
<td>17 (10)</td>
<td>0.39 (0.21; 0–1.37)</td>
<td></td>
</tr>
<tr>
<td>pT3a, pT3b, pT3c, pT4</td>
<td>53 (31)</td>
<td>0.42 (0.29; 0–4.40)</td>
<td></td>
</tr>
<tr>
<td>Regional lymph node involvement</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pNX/pN0</td>
<td>162 (94)</td>
<td>0.34 (0.23; 0–4.40)</td>
<td>0.232</td>
</tr>
<tr>
<td>pN1/pN2</td>
<td>10 (6)</td>
<td>0.34 (0.32; 0.14–0.86)</td>
<td></td>
</tr>
<tr>
<td>Distant metastases</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M0</td>
<td>148 (86)</td>
<td>0.34 (0.23; 0–4.40)</td>
<td>0.076</td>
</tr>
<tr>
<td>M1</td>
<td>24 (14)</td>
<td>0.34 (0.30; 0.13–0.86)</td>
<td></td>
</tr>
<tr>
<td>2002 TNM Stage Groupings</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>100 (58)</td>
<td>0.30 (0.22; 0–3.00)</td>
<td>0.079</td>
</tr>
<tr>
<td>II</td>
<td>14 (8)</td>
<td>0.39 (0.20; 0–1.37)</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>33 (19)</td>
<td>0.47 (0.26; 0–4.40)</td>
<td></td>
</tr>
<tr>
<td>IV</td>
<td>25 (15)</td>
<td>0.33 (0.29; 0.13–0.86)</td>
<td></td>
</tr>
<tr>
<td>Tumor thrombus</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>136 (79)</td>
<td>0.31 (0.22; 0–3.00)</td>
<td>0.086</td>
</tr>
<tr>
<td>Level 0</td>
<td>21 (12)</td>
<td>0.40 (0.32; 0–1.63)</td>
<td></td>
</tr>
<tr>
<td>Level I–IV</td>
<td>15 (9)</td>
<td>0.55 (0.27; 0–4.40)</td>
<td></td>
</tr>
<tr>
<td>Nuclear grade</td>
<td></td>
<td></td>
<td>0.044</td>
</tr>
<tr>
<td>1, 2</td>
<td>72 (42)</td>
<td>0.26 (0.20; 0–1.66)</td>
<td></td>
</tr>
<tr>
<td>3, 4</td>
<td>100 (58)</td>
<td>0.40 (0.24; 0–4.40)</td>
<td></td>
</tr>
<tr>
<td>Coagulative tumor necrosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Absent</td>
<td>126 (73)</td>
<td>0.30 (0.22; 0–3.00)</td>
<td>0.003</td>
</tr>
<tr>
<td>Present</td>
<td>46 (27)</td>
<td>0.46 (0.30; 0–4.40)</td>
<td></td>
</tr>
</tbody>
</table>
gleaned from the current data, although retention of the shed from tumor cells or is released by dying cells cannot be teased and degradation. Whether region of B7-H1 may be more susceptible to serum pro-forms of coregulatory molecules (35). The intracellular from affinity-purified preparations. It has been proposed detected the presence of intracellular B7-H1 sequences remains an unresolved question. Thus far, we have not full-length and truncated or membrane-clipped forms responses.

In contradistinction to studies reporting detection of sB7-H1 (1, 3, 4, 6, 8), our study included biochemical confirmation of our analyte as B7-H1. Utilizing microsequencing of sB7-H1 isolated by affinity chromatography with 2.2B ELISA capture antibody, we have determined that sB7-H1 derived from B7-H1 tumor cell lines retains the extracellular PD-1–binding domain. Because of limited individual patient volumes and technical concerns over pooling a large number of patient samples, sB7-H1 biochemical characterization necessitated the use of tumor cell culture supernates. In vitro tumor-derived sB7-H1 retained the signaling domain necessary for interacting with PD-1 on T cells and delivering immunoinhibitory signals. sB7-H1 may be a contributing factor in compromising antitumoral immune responses.

Whether sB7-H1 molecules comprise a population of full-length and truncated or membrane-clipped forms remains an unresolved question. Thus far, we have not detected the presence of intracellular B7-H1 sequences from affinity-purified preparations. It has been proposed that metalloproteinases may generate truncated soluble forms of coregulatory molecules (35). The intracellular region of B7-H1 may be more susceptible to serum proteases and degradation. Whether in vivo sB7-H1 is actively shed from tumor cells or is released by dying cells cannot be gleaned from the current data, although retention of the extracellular PD-1–binding domains suggests that the presence of sB7-H1 may be one means by which tumors compromise immune responses.

This study distinguishes itself from past reports of other soluble B7-homologues—sB7-H4 in the sera of ovarian cancer (3) and RCC (5) patients and sB7-H3 in the sera of lung cancer patients (36)—because biochemical proof for the presence of the purported molecule was provided; a larger sample size was studied; and a statistically significant correlation between sB7-H1 and the pathologic features of tumor size, primary tumor classification, nuclear grade, and tumor necrosis was established. Our study is the first to report an association of an sB7-H1 ligand with long-term patient outcome. Increased levels of sB7-H1 resulted in an elevated risk of death. The association of sB7-H1 levels with death was attenuated after adjusting for the SSIGN score, however, indicating that an even larger study will be needed to establish the utility of sB7-H1 as an independent prognostic biomarker (37). Nevertheless, we believe that our results provide potential insight into the mechanism by which a ccRCC becomes clinically advanced.

These findings are consistent with our previous immunohistochemical studies wherein it was determined that expression of B7-H1 and B7-H4 correlated with different ccRCC pathologic features. Distinct immunohistochemical expression patterns of membrane B7-H1 (tumor cells) and membrane B7-H4 (tumor vasculature) may account for these varying associations. It is possible that simultaneously determining sB7-H1 and sB7-H4 levels might have more prognostic value than either soluble marker alone, and studies are currently underway to test this possibility.

These results warrant further investigation. In this cohort, 8 patients (5%) were treated preoperatively for metastatic disease which was not sufficient to evaluate the influence of various systemic treatments on preoperative sB7-H1 levels. Although we identified elevated preoperative sB7-H1 levels among patients with more aggressive tumors, it is not known whether sB7-H1 levels fluctuate during tumor progression or remission. Similarly, although we determined that sB7-H1 levels in ccRCC patients were significantly higher than in normal controls, this study was not designed to establish sB7-H1 as a screening tool. Rather, the goal of this study was to investigate associations of preoperative sB7-H1 levels with pathologic features and patient outcome for patients with confirmed ccRCC.

Treatments to inactivate or remove sB7-H1 molecules may be clinically beneficial. Surgical excision of the primary ccRCC could remove a major reservoir of sB7-H1, resulting in a precipitous decline in postsurgery sB7-H1 levels and opening a window of opportunity for augmenting immunoreactivity to residual tumor cells. However, circulating sB7-H1 may be replenished by B7-H1–expressing metastatic tumors. It is conceivable that both nonsurgical treatments and antitumor responses themselves could inadvertently exacerbate sB7-H1 levels by inducing the release of active sB7-H1 by dying ccRCC cells. As phase I clinical trials begin, novel antibody capture therapies might offer a means

![Figure 4. Significant associations of preoperative sB7-H1 levels with pathologic features. Error bars, SEM.](https://example.com/figure4.png)
to inactivate or remove noxious immunosuppressive sB7-H1 molecules and may have clinical benefit.

Disclosure of Potential Conflicts of Interest

Both E.D. Kwon and the Mayo Clinic have received royalties greater than the federal threshold for significant financial interest from the licensing to Medarex of technology related to B7-H1. In addition, E.D. Kwon and the Mayo Clinic have contractual rights to receive future royalties from the licensing of this technology. In addition, some of the authors (E.D. Kwon, X. Frigola, and H. Dong) have filed patents for potential use of B7-H1, B7-H3, and B7-H4 as prognostic markers for assessment of cancer.

Acknowledgments

We thank Carol Preissner, Diana Gil-Pages, Adam Schrum and the Mayo Proteomics Research Center for technical assistance with our studies; Tom Beito at the Mayo Antibody Hyridoma Core Facility for producing 5H1-A3 and 2.2B monoclonal antibody hybridomas; and Allan Dietz, Michael Gustafson, and Mayo Clinic Department of Transfusion Medicine personnel for help obtaining normal control samples.

References


29. Inman BA, Sebo TJ, Frigola X, Dong H, Bergstrahl EJ, Frank I, et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and

Clinical Cancer Research

Received January 28, 2010; revised November 22, 2010; accepted February 9, 2011; published OnlineFirst February 25, 2011.


Identification of a Soluble Form of B7-H1 That Retains Immunosuppressive Activity and Is Associated with Aggressive Renal Cell Carcinoma

Xavier Frigola, Brant A. Inman, Christine M. Lohse, et al.


Updated version: Access the most recent version of this article at: doi:10.1158/1078-0432.CCR-10-0250

Supplementary Material: Access the most recent supplemental material at: http://clincancerres.aacrjournals.org/content/suppl/2011/03/31/1078-0432.CCR-10-0250.DC1

Cited articles: This article cites 36 articles, 14 of which you can access for free at: http://clincancerres.aacrjournals.org/content/17/7/1915.full#ref-list-1

Citing articles: This article has been cited by 11 HighWire-hosted articles. Access the articles at: http://clincancerres.aacrjournals.org/content/17/7/1915.full#related-urls

E-mail alerts: Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions: To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions: To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.